132 related articles for article (PubMed ID: 16043258)
1. Promoter methylation of genes in bronchial lavages: a marker for early diagnosis of primary and relapsing non-small cell lung cancer?
de Fraipont F; Moro-Sibilot D; Michelland S; Brambilla E; Brambilla C; Favrot MC
Lung Cancer; 2005 Nov; 50(2):199-209. PubMed ID: 16043258
[TBL] [Abstract][Full Text] [Related]
2. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
Kim H; Kwon YM; Kim JS; Lee H; Park JH; Shim YM; Han J; Park J; Kim DH
J Clin Oncol; 2004 Jun; 22(12):2363-70. PubMed ID: 15197197
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
[TBL] [Abstract][Full Text] [Related]
4. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of resected bronchial margins: a field defect of changes?
Guo M; House MG; Hooker C; Han Y; Heath E; Gabrielson E; Yang SC; Baylin SB; Herman JG; Brock MV
Clin Cancer Res; 2004 Aug; 10(15):5131-6. PubMed ID: 15297416
[TBL] [Abstract][Full Text] [Related]
6. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH
Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724
[TBL] [Abstract][Full Text] [Related]
7. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer.
Grote HJ; Schmiemann V; Geddert H; Bocking A; Kappes R; Gabbert HE; Sarbia M
Cancer; 2006 Apr; 108(2):129-34. PubMed ID: 16444703
[TBL] [Abstract][Full Text] [Related]
8. Promoter methylation primarily occurs in tumor cells of patients with non-small cell lung cancer.
De Jong WK; Verpooten GF; Kramer H; Louwagie J; Groen HJ
Anticancer Res; 2009 Jan; 29(1):363-9. PubMed ID: 19331174
[TBL] [Abstract][Full Text] [Related]
9. Aberrant DNA methylation profiles of non-small cell lung cancers in a Korean population.
Kim DS; Cha SI; Lee JH; Lee YM; Choi JE; Kim MJ; Lim JS; Lee EB; Kim CH; Park TI; Jung TH; Park JY
Lung Cancer; 2007 Oct; 58(1):1-6. PubMed ID: 17532092
[TBL] [Abstract][Full Text] [Related]
10. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
[TBL] [Abstract][Full Text] [Related]
11. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer.
Fujiwara K; Fujimoto N; Tabata M; Nishii K; Matsuo K; Hotta K; Kozuki T; Aoe M; Kiura K; Ueoka H; Tanimoto M
Clin Cancer Res; 2005 Feb; 11(3):1219-25. PubMed ID: 15709192
[TBL] [Abstract][Full Text] [Related]
12. Serum DNA as a tool for cancer patient management.
Ramirez JL; Taron M; Balaña C; Sarries C; Mendez P; de Aguirre I; Nuñez L; Roig B; Queralt C; Botia M; Rosell R
Rocz Akad Med Bialymst; 2003; 48():34-41. PubMed ID: 14737938
[TBL] [Abstract][Full Text] [Related]
13. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
14. High frequency of p16 promoter methylation in non-small cell lung carcinomas from Chile.
Guzman LM; Koriyama C; Akiba S; Eizuru Y; Castillo D; Corvalan A; Aguayo FR
Biol Res; 2007; 40(3):365-72. PubMed ID: 18449464
[TBL] [Abstract][Full Text] [Related]
15. Anthracotic index and DNA methylation status of sputum contents can be used for identifying the population at risk of lung carcinoma.
Konno S; Morishita Y; Fukasawa M; Shu Y; Wang D; Tanaka R; Minami Y; Iijima T; Noguchi M
Cancer; 2004 Dec; 102(6):348-54. PubMed ID: 15481085
[TBL] [Abstract][Full Text] [Related]
16. Genetic deletions in sputum as diagnostic markers for early detection of stage I non-small cell lung cancer.
Li R; Todd NW; Qiu Q; Fan T; Zhao RY; Rodgers WH; Fang HB; Katz RL; Stass SA; Jiang F
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):482-7. PubMed ID: 17255269
[TBL] [Abstract][Full Text] [Related]
17. Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment.
Hsu HS; Chen TP; Wen CK; Hung CH; Chen CY; Chen JT; Wang YC
J Pathol; 2007 Dec; 213(4):412-9. PubMed ID: 17973238
[TBL] [Abstract][Full Text] [Related]
18. p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients.
Ulivi P; Zoli W; Calistri D; Fabbri F; Tesei A; Rosetti M; Mengozzi M; Amadori D
J Cell Physiol; 2006 Mar; 206(3):611-5. PubMed ID: 16222700
[TBL] [Abstract][Full Text] [Related]
19. Assessing abnormal gene promoter methylation in paraffin-embedded sputum from patients with NSCLC.
Olaussen KA; Soria JC; Park YW; Kim HJ; Kim SH; Ro JY; André F; Jang SJ
Eur J Cancer; 2005 Sep; 41(14):2112-9. PubMed ID: 16129599
[TBL] [Abstract][Full Text] [Related]
20. Aberrant p16 promoter methylation among Greek lung cancer patients and smokers: correlation with smoking.
Georgiou E; Valeri R; Tzimagiorgis G; Anzel J; Krikelis D; Tsilikas C; Sarikos G; Destouni C; Dimitriadou A; Kouidou S
Eur J Cancer Prev; 2007 Oct; 16(5):396-402. PubMed ID: 17923809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
